The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...
FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
Investor's Business Daily on MSN23h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
Prime Medicine, Inc. has recently entered into a strategic research collaboration and license agreement with Bristol Myers Squibb (BMS) to develop and commercialize multiple prime edited ex vivo ...
Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...
You’ve likely heard that penny stocks are high-risk investments, and if so, you’ve heard right. However, a significant part ...
IGM Biosciences shifts focus to autoimmune diseases, reduces oncology research, and appoints former Bristol Myers Squibb ...
Dividend investing has become increasingly popular over time, as generating regular income remains a key focus for investors.
Leerink Partners analyst David Risinger has maintained their neutral stance on BMY stock, giving a Hold rating on September 26. David Risinger ...
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback